
Sahajanand Medical Technologies Limited

Investor Presentation

Q2 FY2026-27



Safe Harbor Statement

This presentation is not an offer, invitation, solicitation or recommendation to buy, sell or subscribe for any securities of the Company. It should not be the basis for any contract, commitment or investment decision. Any offering of securities will be made only through a formal offering document.

Forward-looking statements

This presentation contains statements about the Company's future plans, strategy, expected performance, market opportunity, new products, regulatory approvals, capacity, costs, margins and industry outlook. These are "forward-looking statements". They are often, but not always, identified by words such as "expect", "anticipate", "believe", "intend", "plan", "estimate", "project", "may", "will", "should" and "target". Forward-looking statements are based on management's current views and assumptions. They are not guarantees of future performance. They involve known and unknown risks and uncertainties, many outside the Company's control, so actual results may differ materially from what is stated or implied. Please do not place undue reliance on them.

Factors that could cause results to differ

These include, but are not limited to: economic, political and market conditions in India and in the countries where we operate, including inflation, interest rates, currency movements and geopolitical events; competition, pricing pressure and changes in customer demand; our ability to deliver on our strategy, growth and expansion plans, including acquisitions and their integration; regulatory approvals, inspections and compliance, and changes in laws; product development, clinical or technical outcomes and launch timelines; supply chain, input cost, manufacturing capacity and quality risks; intellectual property and litigation matters; quarter-to-quarter variations in revenue caused by order timing, deferrals or the nature of our business; technology, cybersecurity and operational disruptions; and other risks described in our regulatory filings.

Accuracy of information

We believe the information in this presentation is reliable, but we make no representation or warranty, express or implied, that it is accurate, complete or fair. It may not include everything you consider important. To the fullest extent permitted by law, the Company, its directors, officers and employees accept no liability for any loss arising from use of, or reliance on, this presentation.

Financial information

Figures are drawn from the Company's financial results. Please read this presentation together with the full results and disclosures on the Company's website (https://smtpl.com/) and on the websites of the BSE and NSE, the filed financial results prevail. Some measures used here, such as EBITDA, margins, return ratios are not defined under Ind AS, and may be calculated differently by other companies. Comparisons with earlier periods may be affected by acquisitions, one-off items or reclassification. Past performance is not a guide to future results.

Third-party and industry data

Market, industry and competitor data comes from sources we consider reliable. We have not independently verified it and do not guarantee it. Views or projections from third parties are not adopted by the Company, which is not responsible for them.

Products and medical information

Products or brands mentioned are for illustration only and are not an endorsement, advertisement or recommendation. Product information is general, may vary by country, and is not complete medical information or a substitute for advice from a qualified healthcare professional. Availability depends on local approvals and patents.

No obligation to update

This presentation speaks only as of its date. Except as required by law or by stock exchange regulations, the Company is not obliged to update or revise any information or forward-looking statement, whether because of new information, future events or otherwise.

Distribution

This presentation is not intended for distribution in any jurisdiction where doing so would be unlawful. Anyone receiving it should inform themselves of, and follow, any such restrictions.

Contents

Q2 and H1 FY27 investor presentation

		Slides
1	**Management commentary** Message from the Managing Director and CEO	4
2	**Q2 and H1 FY27 financial performance** Results snapshot, product and regional mix, and financial KPIs: P&L, balance sheet and returns, cash conversion and cash flow	5 – 12
3	**Operating KPIs and asset efficiency** Global presence, capacity utilisation and fixed asset turnover	13 – 15
4	**Product pipeline and regulatory progress** Hydra TAVI, Hydra Elevate, AVDC 1.5, Sironity DCB and EU MDR status	16 – 21
5	**Company overview** Business model, products, R&D, manufacturing, leadership and board	22 – 30

Management Commentary

Q2 and H1 FY27: our first results as a listed company

Q2 FY27 marks our first results as a listed company. I would like to thank our shareholders, physicians, partners and employees for the trust they placed in SMT through our listing on 23rd October 2026, and we remain committed to earning that trust through consistent execution.

We delivered a strong first half. H1 FY27 revenue grew 25% to ₹7,251 mn and EBITDA grew 43% to ₹1,141 mn, with the EBITDA margin expanding by about 200 basis points to 15.7%. Q2 FY27 was our best quarter yet, with the highest-ever quarterly revenue, EBITDA and PAT.

We also strengthened our portfolio. Sironity, our sirolimus drug-coated balloon, is commercialized in India, and our TAVI platform has moved forward with Hydra Elevate and the redesigned AVDC 1.5 delivery system.

Operational efficiency remains a key priority. We are focused on improving margins through a richer product mix, vertical integration of critical components, better utilisation of our plants and tighter control of overheads, to deliver profitable, sustainable growth.

Our priorities are unchanged: disciplined execution, sustained investment in R&D and clinical evidence, and better quality of cash flows.



Bhargav Dhirajlal Kotadia

Managing Director and
Chief Executive Officer

Q2 and H1 FY27 Financial Performance

Record Quarter: Highest-Ever Revenue, EBITDA and PAT in Q2 FY27


Revenue +25%, EBITDA +37% and PAT +27% year on year in Q2 FY27

	Revenue	EBITDA	PAT
Q2 FY27 ★ Record quarter	**₹3,734 mn** ↑ +24.7% YoY	**₹656 mn** ↑ +36.6% YoY 17.6% margin (Q2 FY26: 16.0%)	**₹265 mn** ↑ +26.6% YoY 7.1% margin (Q2 FY26: 7.0%)
H1 FY27	**₹7,251 mn** ↑ +24.9% YoY	**₹1,141 mn** ↑ +43.4% YoY 15.7% margin (H1 FY26: 13.7%)	**₹416 mn** ↑ +7.5% YoY 5.7% margin (H1 FY26: 6.7%) +38.8% excl. one-off tax credit in H1 FY26

H1 FY27 Revenue Up 25%, With Growth Across All Three Categories

Revenue mix and year-on-year growth by product category, Q1, Q2 and H1 FY27


Q1 FY27



YoY growth

+24.0%	+10.3%	+41.7%


Q2 FY27



YoY growth

+9.1%	+39.7%	+62.1%

H1 FY27 (Q1 + Q2)



YoY growth

+16.1%	+24.7%	+52.0%

KEY TAKEAWAYS

Other grew fastest: +42% in Q1 and +62% in Q2, led by IVUS

SH accelerated: +40% in Q2 after +10% in Q1

VI remains the core: 58% of H1 revenue, up 16% year on year.

VI Stents & balloons **SH** TAVI & occluders **Other** Trading products


Growth % vs the same period of FY26.

H1 FY27 Revenue Up 25%, Led by RoW (+37%) and Europe (+23%)

Revenue share and year-on-year growth by region, H1 FY27

India





Share of H1

+10.4%


H1 YoY growth

₹1,720 mn

Q1	₹838 mn	**+6.2%**
Q2	₹882 mn	**+14.8%**

Europe





Share of H1

+23.4%


H1 YoY growth

₹2,627 mn

Q1	₹1,320 mn	**+23.5%**
Q2	₹1,307 mn	**+23.4%**

RoW (APAC, RCIS, LATAM, MEA)





Share of H1

+37.1%

H1 YoY growth

₹2,904 mn

Q1	₹1,359 mn	**+42.8%**
Q2	₹1,545 mn	**+32.4%**

KEY TAKEAWAYS

India picked up: +15% in Q2 after +6% in Q1; share down to 24% as other regions grew faster.

Europe steady: +23% in both quarters, holding about 36% of revenue.

RoW grew fastest: +43% in Q1 and +32% in Q2; now 40% of H1 revenue, the largest region.

Record Q2: EBITDA Up 37% and PAT Up 27% on 25% Revenue Growth

Consolidated profit and loss summary, Q2 and H1 FY27 (₹ mn)

₹ mn	Q2 FY27	Q2 FY26	YoY	H1 FY27	H1 FY26	YoY
Revenue from operations	**3,734**	**2,995**	**+24.7%**	**7,251**	**5,804**	**+24.9%**
Cost of goods sold	(956)	(708)		(1,867)	(1,396)	
Gross profit	**2,778**	**2,287**	**+21.5%**	**5,384**	**4,408**	**+22.1%**
Gross margin	*74.4%*	*76.4%*	*-197 bps*	*74.3%*	*76.0%*	*-170 bps*
Employee benefits expense	(1,013)	(863)		(1,987)	(1,721)	
% of revenue	*27.1%*	*28.8%*	*-169 bps*	*27.4%*	*29.7%*	*-226 bps*
Other expenses	(1,110)	(945)		(2,256)	(1,891)	
% of revenue	*29.7%*	*31.5%*	*-182 bps*	*31.1%*	*32.6%*	*-146 bps*
EBITDA	**656**	**480**	**+36.6%**	**1,141**	**796**	**+43.4%**
EBITDA margin	*17.6%*	*16.0%*	*+154 bps*	*15.7%*	*13.7%*	*+202 bps*
Other income	22	23		49	55	
Depreciation (PPE and right-of-use assets)	(165)	(129)		(321)	(249)	
Amortisation of intangible assets[1]	(44)	(43)		(92)	(85)	
Finance costs	(68)	(60)		(134)	(118)	
Profit before tax	**401**	**271**	**+47.9%**	**644**	**399**	**+61.2%**
Tax (current and deferred)	(136)	(62)		(228)	(100)	
Tax credit relating to earlier periods	–	–		–	87	
Profit after tax	**265**	**209**	**+26.6%**	**416**	**386**	**+7.5%**
PAT margin	*7.1%*	*7.0%*	*+11 bps*	*5.7%*	*6.7%*	*-93 bps*
PAT excluding earlier-period tax credit	*265*	*209*	***+26.6%***	*416*	*299*	***+38.8%***

Revenue growth in constant currency

Q2 FY27 **~16%** reported 24.7%

H1 FY27 **~15%** reported 24.9%

[1] Mainly brand & technology and customer relationships recognized on past acquisitions. These intangibles will be fully amortized by Mar 2027, after which this charge will largely cease.

Returns Improving: ROCE at 16.7% and ROE at 11.2%


Balance sheet in sources and application of funds format (₹ mn)

₹ mn	30-Sep-26	31-Mar-26
Total Equity	7,453	7,023
Borrowings	**3,017**	**2,695**
Sources of Funds	**10,470**	**9,718**
Fixed Assets	3,537	3,524
Net Non-current Assets / (Liabilities)	787	794
Inventory (At Cost)	3,303	3,091
Trade Receivables	3,181	2,863
Trade Payables & Other current Liabilities (net of assets)	(1,481)	(1,669)
Net Working Capital	**5,003**	**4,285**
Capital Employed	**9,327**	**8,602**
Cash & Cash Equivalents	**1,143**	**1,116**
Application of Funds	**10,470**	**9,718**
ROCE (EBIT / capital employed)	**16.7%***	**12.2%**
ROE (PAT / total equity)	**11.2%***	**9.8%**

* Annualised: Sep-26 ROCE and ROE use H1 FY27 EBIT × 2 and PAT × 2 respectively.

Sharper Focus on Cash Conversion: Cycle Down 16 Days to 128

Receivable, inventory and payable days, FY25 to H1 FY27



DAYS

Days	FY25	FY26	H1 FY27
Receivable days	85	83	75
Inventory days	92	87	79
Payable days	33	32	26
Cash conversion cycle	**144**	**138**	**128**

WHAT MOVED, FY26 TO H1 FY27


–8 days
Receivables
faster collections

–8 days
Inventory
leaner stock

+6 days
Payables

Cash From Operations Up 2.6x Since FY24, Converting 62% of EBITDA

Cash conversion, free cash flow and leverage, FY24 to H1 FY27 (₹ mn)



CASH FLOW

₹ mn	FY24	FY25	FY26	H1 FY27
Cash from operations	**411**	**735**	**1,052**	**473**
Net capex	(393)	(477)	(884)	(415)
Lease payments	(116)	(94)	(152)	(76)
Free cash flow after leases (before interest on borrowings)	**(98)**	**164**	**16**	**(18)**

LEVERAGE

Net debt (period end)	951	1,159	1,911	2,235
Net debt / EBITDA	**0.86x**	**0.91x**	**1.12x**	**0.98x***


* Annualised: net debt / EBITDA for H1 FY27 uses H1 EBITDA × 2. H1 FY27 cash flows are for six months.

Operating KPIs and Asset Efficiency

Broad Global Reach, With Ample Manufacturing Headroom

Countries with commercial presence, installed capacity and capacity utilisation by product and plant

Countries with commercial presence



Installed capacity and utilisation

Product	Plant / line		Capacity (units p.a.) FY26	Capacity (units p.a.) H1 FY27	Capacity utilisation FY26	Capacity utilisation H1 FY27
DES	Surat		780,000	780,000	80%	79%
	Telangana		120,000	180,000	64%	20%
Balloon	PTCA · Surat		660,000	660,000	97%	72%
	PTCA · Telangana		480,000	600,000	85%	57%
	DCB · Surat	New	–	56,000	–	40%
TAVI	Thailand		3,000	3,600	60%	53%
Occluder	Thailand		30,000	30,000	48%	46%

85%+ 65–85% 40–65% <40%


Orange: capacity added or new line in H1 FY27

Countries: commercial presence with at least one product in the period; the H1 FY27 count is not directly comparable with full-year counts.
Capacity utilisation = production ÷ installed capacity for the period; H1 FY27 uses half of annual capacity.

Asset-Light Model, With Telangana Capacity in Place for Growth

Gross tangible fixed asset turnover ratio (GTFAT), before and after the Telangana Plant came on stream

GTFAT, FY20–H1 FY27



Average GTFAT **7.2x**

Average GTFAT, FY23–FY26 **3.7x**

Telangana Plant (FY26)



Plant area in use **33%**

DES capacity utilised **64%**

Catheter capacity utilised **85%**

56% of gross block sits at the Telangana Plant


* Annualised: H1 FY27 revenue × 2.

Product Pipeline and Regulatory Progress

Hydra TAVI Built Through Continuous Clinical Iteration

Valve and delivery system refined generation by generation, each step backed by clinical data

Clinical and regulatory milestones



Valve	**Hydra** Nitinol frame, bovine leaflets, internal skirt · CE mark | CDSCO	**Hydra Elevate** + polymeric external skirt to seal the annulus · CDSCO (Jan 2026)
Delivery system	**AVDC 1.0** Patented system, developed after the acquisition · CE mark | CDSCO	**AVDC 1.5** Braided capsule, zero-lag release, fewer rotations · CE approval FY26

PPI: permanent pacemaker implantation.

Hydra Elevate: The Proven Hydra Valve, Plus an External Skirt

Same platform carried forward; a polymeric external skirt added to seal the annulus

Existing: Hydra




- Nitinol self-expanding frame
- Bovine leaflets, internal skirt
- Supra-annular leaflet position
- Re-sheathable and repositionable

Approvals: CE mark | CDSCO

Polymeric external skirt

Seals the annulus to reduce paravalvular leak

New: Hydra Elevate (TAVI 2.0)



- **Polymeric external skirt** that seals the annulus
- Designed to reduce paravalvular leak
- Same frame, leaflets and internal skirt as Hydra

Approvals: CDSCO

AVDC 1.5: Redesigned for Stable, Predictable Deployment

Refined from AVDC 1.0 with a braided capsule, longer in-line sheath and stronger shaft

Existing: AVDC 1.0



Patented delivery system developed after the Vascular Innovations acquisition

CE mark | CDSCO

New: AVDC 1.5



Next-generation delivery system; CE approval received in FY26

CE mark | CDSCO

What's new in AVDC 1.5

Lag reduced to zero

Direct 1:1 response between knob and capsule

Fewer rotations to deploy

Simpler, faster deployment

Longer in-line sheath

Better coaxial tracking and stability

More robust shaft

Greater pushability through the delivery path


Ergonomic design

Improves the user experience for the implanting physician

Sironity: SMT's Sirolimus Drug-Coated Balloon

Sironity
Sirolimus Drug Coated PTCA Balloon Catheter

Brings together SMT's drug-formulation and balloon platforms



★ Commercialised in India

Three design levers

1. **Duo nano core formulation**
2. **Proven non-compliant balloon platform**
3. **Higher dose, full-circumference coating**

84 sizes: 1.50–5.00 mm, 10–40 mm long

Rapid exchange, 6F guide compatible

30–60 second inflation

DCB: drug-coated balloon.

Supraflex Cruz Certified; Four More on Track Ahead of MDR Deadline

Progress of each product through the EU MDR certification stages


Product	Notified body	Submitted	Stage I audit	Stage II audit	Certified
Supraflex Cruz EU MDR certification received.	TUV SUD	●	●	●	✓
Pipit NC Stage I and II audits completed; technical documentation review underway.	Szutest	●	●	●	○
Pipit SC Stage I and II audits completed; technical documentation review underway.	Szutest	●	●	●	○
Hydra Technical file submitted; first reviewer questions answered.	PCBC	●	○	○	○
Cocoon Technical file submitted; first reviewer questions answered.	PCBC	●	○	○	○

● Completed ○ Pending **EU MDR transition period ends 31-Dec-2027.**

Company Overview

Focused on Class III Medical Devices With High Entry Barriers

Technical complexity, stringent scrutiny, large clinical data and KOL engagement requirements



Barriers to entry in Class III medical devices

Segment with high entry barriers and sustainable technical moat

- ✓ ***High-risk devices need substantial R&D investments and have long gestation periods***
- ✓ ***Significant investments are required for clinical trials and building brand reputation***
- ✓ ***Stringent regulations for approvals and extensive clinical data requirements***
- ✓ ***Requirement of significant scientific selling and KOL engagements to drive adoption***
- ✓ ***Prolonged approval timelines for high risk devices***

Technologically Advanced and “Most Deliverable” Stent in its Class…

Most deliverable and world’s 1st CE certified biodegradable polymer stent

World’s 1st CE approved *biodegradable polymer coated DES*

Most Deliverable DES in its class, *preferred in complex PCI*

28,383 patients *incl. high risk and geriatric patients*

Published in

LANCET *Impact factor 109.0*

NEJM *Impact factor 84.5*

Commercialized in ***71 markets*** *b/w FY24-Jun’26*

NEJM: New England Journal of Medicine
Impact factor represents the average number of times articles published in a journal were cited in a given year

Numerically superior against leading brands

TALENT all-comers trial: Supraflex was compared with Xience in a population open to almost any patient with the condition studied. **At 12 months, Supraflex was non-inferior to Xience on device-oriented endpoints,** with a lower rate of clinically indicated target lesion revascularisation in the per-protocol analysis.

Source: TALENT clinical trial, 12-month results (Chairman: Dr Patrick W. Serruys)

Comprehensive clinical coverage

Indications	SMT	
	CY 2019 >	CY 2025 >
De Novo Stenotic lesion	✓	✓
Bifurcation Lesions		✓
Diabetic Patients		✓
DAPT / HBR		✓
Elderly Patients		✓
In-stent Restenosis (ISR)	✓	✓
Multi Vessel PCI		✓
Small Vessel		✓
STEMI		✓
Left main (LM) disease		✓

...Along with Advanced Structural Heart Products (TAVI and Occluders)

TAVI: Low permanent pacemaker implantation rate (PPI)

Self expandable *Nitinol stent frame TAVI 'Hydra'*


Published in ***CCI*** ***JACC***

Commercialized in ***36 markets*** *b/w FY24-Jun'26*

Approval Update	*CE mark, CDSCO*	*Hydra (no skirt)*	*CDSCO*	*Hydra Elevate (ext. skirt)*	*CE mark, CDSCO*	*AVDC*

CCI: Catheterization and Cardiovascular Interventions, JACC: Journal of the American College of Cardiology

PPI after 30 days of implant *(lower is better)*



Occluder: Platinum coated to minimize Nickel leaching

Platinum coated *'Cocoon' Occluder to minimize Nickel leaching*

Published in ***HJC*** ***FCM***

Commercialized in ***55 markets*** *b/w FY24-Jun'26(1)*

No device related erosion or allergy

"implantation of CSO provided satisfactory procedural and follow-up results with high success and no device-related cardiac erosions and nickel allergy"

– Dr. Basil (Vasilios) D. Thanopoulos, IASO Children's Hospital, Greece


HJC: Hellenic Journal of Cardiology, FCM: Frontiers in Cardiovascular Medicine

Proven R&D Capabilities Across Products and Platform Technologies

Structured teams, working in collaborative environment to launch innovative products

Robust in-house R&D capabilities

- R&D team of **156 members,** with several members having Masters and PhDs
- Replaced externally sourced balloon catheters with **self manufactured balloon catheters leading to cost saving** and improved quality control
- Track record of safety, efficacy and generating clinical data
- **R&D spend at ~9–10% of revenue**, FY24 to H1 FY27



- **Innovation recognized and awarded**
  - "***Excellence in Clinical Evidence***" for 35,000+ patient clinical program by CSI NIC, 2025
  - "***CPHI India Pharma 2022 Award in Excellence in R&D - Development of new product/technology***" by Informamarkets, 2022
  - "***National Award 2022 for successful development and commercialization of indigenous technology***" by the Technology Development Board (TDB)

Robust in-house technologies and IPs

- **Catheter manufacturing**
- **Laser cutting**
- **Drug coating**
- **Drug and polymer formulation**
- **Medical grade tubing extrusion**
- **Custom equipment design**
- **Advanced alloy processing**
- **Valve manufacturing**
- **Braiding & Lamination**

Global R&D facilities

- India (DSIR approved)
- Nonthaburi, Thailand (GMP, CE certified)

Robust IP

118	79	5	75
Patents granted	*Additional patents in pipeline*	*Design registrations*	*Clinical studies (incl. ongoing)*

Partnerships

- ***Institute of Chemical Technology***
- ***Sardar Vallabhbhai National Institute of Technology (SVNIT)***
- ***Technology Development Board***

Integrated Manufacturing across India and Thailand with Room to Scale

Annual capacity and utilisation by plant, with critical components brought in-house

Three plants, globally accredited

	Sachin SEZ, Surat (India)	Telangana (India)	Nonthaburi (Thailand)
Area utilisation	100%	33%	100%
DES	780,000 | 79%	180,000 | 20%	–
Catheter	660,000 | 72%	600,000 | 57%	–
TAVI	–	–	3,600 | 53%
Occluder	–	–	30,000 | 46%
Key approvals	CE, MDSAP, CDSCO ANVISA and TGA (via MDSAP) ISO 13485:2016	CDSCO ISO 13485:2016	CE, ANVISA, Korean GMP Thai FDA, ISO 13485:2016

Annual capacity (units) | capacity utilisation %

Room to scale: Telangana uses only a third of its plant area, leaving space to add DES and catheter capacity as demand grows.

Vertical integration

Technologies in-house

- Drug and polymer formulation
- Laser cutting
- Valve manufacturing
- Catheter manufacturing
- Nitinol processing — WIP
- Extrusion and braiding — WIP

WIP: capability being built in-house

Leadership Team with Global Medtech Experience (1/2)

Senior executives with global medtech experience across R&D, manufacturing and business development

Bhargav Dhirajlal Kotadia
Managing Director & CEO



- Joined SMT in 2013 as Executive Director
- B.Sc. Economics, Purdue University, USA
- "ET 40 under Forty", The Economic Times
- "India's Impactful Healthcare Leaders 2026", ET Edge, The Times Group

Amit Kumar Khandelia
Chief Financial Officer



- Over 20 years in finance; ex-Alkem, Cipla and Tata Teleservices
- Chartered Accountant; Company Secretary, B.Com, St. Xavier's College, Kolkata
- Alumnus of IIM Ahmedabad
- "CA Achiever in the Healthcare Sector", ICAI, 2018

Priyanka Dhirajlal Cohen
Legal Head



- 7 years of experience in the field of litigation ; served as a Trial Attorney with the tax division, US Dept. of Justice
- Juris Doctor cum Laude from Washington College of Law, American University,

Dr. Krishnankutty Sudhir
Chief Medical Officer



- Over 18 years of experience in organizations like Abbott etc.
- Fellow of the Royal Australasian College of Physicians and the Society of Cardiovascular Angiography and Interventions, FSCAI.

Piyush Savalia
Chief Strategy Officer



- 17 years of experience in the field of interventional cardiology
- Bachelor of Pharmaceutical Science from Mumbai University

Anil Suri
Chief Commercial Officer



- 23 years of experience in sales, and marketing, with tenure in Abbott Vascular; Joined SMT in 2023
- MBA from IIM Indore

Leadership Team with Global Medtech Experience (2/2)

Senior executives with global medtech experience across R&D, manufacturing and business development

Manoj Jain
Senior Vice President – Quality & Regulatory Affairs



- 28 years of with expertise in QA, risk management, reg. affairs, and ops. excellence with tenure in Boston Scientific, Biomet Microfixation
- Master's degree in Engg. Mgmt. from Syracuse University, USA

Abhijeet Singhvi
Chief Technology Officer



- 17 years of experience in quality assurance and product compliance with tenure in Boston Scientific, Marlborough; 16 yrs. with SMT
- Master in Biomedical Engineering from Worcester Polytechnic Institute (MA, USA)

Girish Kewalramani
Chief Information Technology



- 24 years of experience in IT across CEAT, Lupin, Indokem and Seforge, 7+ years with SMT
- Graduated from Maharshi Dayanand Saraswati University

Russell Rozario
Senior Vice President - Human Resources



- 30 years of experience in HR with tenure in Metropolis, Unisource etc.; 8+ years with SMT
- B.Sc. Chemistry from K.J. Somaiya College of Science, Diploma in HR from Welingkar Institute of Management

Experienced Board Guiding SMT's Next Phase of Growth

Chaired by a 37-year medtech veteran

Board of Directors



Dhirajlal Kotadia
Chairman Emeritus and Non-Executive Director



Bhargav Dhirajlal Kotadia
Managing Director and CEO



Jose Calle Gordo
Chairperson and Non-Executive Director
Past Organisations - Biosensors & Abbott



Priyanka Dhirajlal Cohen
Non-Executive Director
Past Organisations – Trial Attorney, US Dept. of Justice



Abhishek Rajendrakumar Kabra
Non-Executive Director
MD, Samara Capital



Sonalika Girdharilal Dhar
Independent Director
Global Head - Strategic Investments and Business Development- UPL Limited
Past Organisations – Edelwiess, KPMG



Debasis Panigrahi
Independent Director
Designated Partner – Mridayaa Ventures,
Past Organisations – Nomura



Harvinder Pal Singh
Independent Director
Executive VP & President International – Integra LifeSciences Corporation,
Past Organisations- Abbott

Thank You

Investor Relations
investor.relations@smt.in

Sahajanand Medical Technologies Limited
Corporate Office: 402 & 412, A-Wing, Kanakia Wall Street, Andheri-Kurla Road, Chakala, Andheri (East), Mumbai, Maharashtra – 400 093



SMT

PLEDGED TO SAVE MILLIONS

Scan this QR code o
visit www.smtpl.com
for more information